Table 5.
Isolated papillary muscle data after positive inotropic stimulation
| SHR (n = 13) | SHR-APO (n = 11) | SHR-DM (n = 11) | SHR-DM-APO (n = 10) | ||
|---|---|---|---|---|---|
| PP30 | DT | 13.7 ± 3.09 | 11.1 ± 1.69* | 11.9 ± 3.01 | 10.3 ± 2.87 |
| RT | 1.04 ± 0.30 | 1.06 ± 0.31 | 1.24 ± 0.52 | 1.25 ± 0.62 | |
| +dT/dt | 140 ± 33.4 | 115 ± 23.1* | 105 ± 25.0* | 95.2 ± 27.8 | |
| TPT | 215 ± 17.1 | 209 ± 13.0 | 255 ± 27.0* | 250 ± 22.6# | |
| −dT/dt | 42.6 ± 9.67 | 35.8 ± 4.58 | 32.4 ± 8.73* | 25.1 ± 8.45#§ | |
| 2.5 mM [Ca+2]0 | DT | 12.5 ± 2.78 | 10.3 ± 1.49 | 11.0 ± 2.95 | 9.79 ± 2.85 |
| RT | 0.87 ± 0.30 | 0.90 ± 0.31 | 0.90 ± 0.34 | 0.92 ± 0.52 | |
| +dT/dt | 140 ± 31.9 | 117 ± 21.4 | 108 ± 28.0* | 97.9 ± 28.7 | |
| TPT | 192 ± 16.9 | 186 ± 17.8 | 224 ± 23.2* | 216 ± 15.1# | |
| −dT/dt | 48.3 ± 10.6 | 40.0 ± 6.27 | 38.4 ± 11.6* | 30.7 ± 10.2# | |
| Iso 10−6 M | DT | 11.4 (8.33–13.5) | 9.70 (8.77–10.1) | 9.68 (8.60–10.1) | 9.47 (6.08–10.8) |
| RT | 0.85 ± 0.43 | 0.86 ± 0.34 | 0.84 ± 0.28 | 0.83 ± 0.52 | |
| +dT/dt | 136 ± 34.0 | 118 ± 22.4 | 96.9 ± 26.6* | 96.7 ± 31.7 | |
| TPT | 163 ± 11.1 | 157 ± 9.49 | 184 ± 16.9* | 190 ± 15.8# | |
| −dT/dt | 67.9 ± 16.6 | 58.3 ± 8.03 | 46.4 ± 13.4* | 39.1 ± 13.7# |
Data are expressed as mean ± standard deviation or median and 25th and 75th percentile
SHR spontaneously hypertensive rats; SHR-APO SHR treated with apocynin; SHR-DM diabetic SHR; SHR-DM-APO diabetic SHR treated with apocynin; PP30 30 s post-rest contraction; 2.5 mM [Ca +2 ] 0 extracellular Ca2+ concentration increased to 2.5 mM; Iso 10 −6 M β-adrenergic agonist isoproterenol (10−6 M) added to the nutrient solution; DT peak of developed tension (g/mm2); RT resting tension (g/mm2); +dT/dt maximum rate of tension development (g/mm2/s); TPT time to peak tension (ms); −dT/dt maximum rate of tension decline (g/mm2/s)
Two-factor ANOVA; * p < 0.05 vs SHR; # p < 0.05 vs SHR-APO; § p < 0.05 vs SHR-DM